27 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp01851 | Bombina orientalis Bombinin H-BO1 | IIGPVLGLVGKALGGLL | Oriental Fire-bellied Toad Bombinin H-BO1 | Anti-proliferative effects | MTT assay | Hep G2 | Human hepatoma | IC50 : 3.61 μM |
| dbacp01852 | Bombina orientalis Bombinin H-BO1 | IIGPVLGLVGKALGGLL | Oriental Fire-bellied Toad Bombinin H-BO1 | Anti-proliferative effects | MTT assay | SK-HEP-1 | Human hepatoma | IC50 : 8.08 μM |
| dbacp01853 | Bombina orientalis Bombinin H-BO2 | IIGPVLGLVGKALGGLL | Oriental Fire-bellied Toad Bombinin H-BO1 | Anti-proliferative effects | MTT assay | Huh7 | Human hepatoma | IC50 : 8.42 μM |
| dbacp01854 | Bombina orientalis Bombinin H-BO3 | GIGSAILSAGKSIIKGLAKGLAEHF | Oriental Fire-bellied Toad Bombinin H-BO1 | Anti-proliferative effects | MTT assay | Hep G2 | Human hepatoma | IC50 : 3.61 μM |
| dbacp01855 | Bombina orientalis Bombinin H-BO4 | GIGSAILSAGKSIIKGLAKGLAEHF | Oriental Fire-bellied Toad Bombinin H-BO1 | Anti-proliferative effects | MTT assay | SK-HEP-1 | Human hepatoma | IC50 : 8.08 μM |
| dbacp01856 | Bombina orientalis Bombinin H-BO5 | GIGSAILSAGKSIIKGLAKGLAEHF | Oriental Fire-bellied Toad Bombinin H-BO1 | Anti-proliferative effects | MTT assay | Huh7 | Human hepatoma | IC50 : 8.42 μM |
| dbacp01860 | Bombinin H-BO1 | IIGPVLGLVGKALGGLL | Oriental Fire-bellied Toad | Anti-proliferative effects | MTT assay | Hep G2 | Human hepatoma | IC50 : 3.61 μM |
| dbacp01861 | Bombinin H-BO1 | IIGPVLGLVGKALGGLL | Oriental Fire-bellied Toad | Anti-proliferative effects | MTT assay | SK-HEP-1 | Human hepatoma | IC50 : 8.08 μM |
| dbacp01862 | Bombinin H-BO1 | IIGPVLGLVGKALGGLL | Oriental Fire-bellied Toad | Anti-proliferative effects | MTT assay | Huh8 | Human hepatoma | IC50 : 8.42 μM |
| dbacp01863 | Bombinin H-BO1 | IIGPVLGLVGKALGGLL | Skin secretion, Oriental fire-bellied toad, China, Asia | Anti-proliferative effects | MTT assay | Hep G2 | Human hepatoma cancer | IC50 : 3.61 μM |
| dbacp01864 | Bombinin H-BO1 | IIGPVLGLVGKALGGLL | Skin secretion, Oriental fire-bellied toad, China, Asia | Anti-proliferative effects | MTT assay | SK-HEP-1 | Human hepatoma cancer | IC50 : 8.08 μM |
| dbacp01865 | Bombinin H-BO1 | IIGPVLGLVGKALGGLL | Skin secretion, Oriental fire-bellied toad, China, Asia | Anti-proliferative effects | MTT assay | Huh7 | Human hepatoma cancer | IC50 : 8.42 μM |
| dbacp01867 | Bombinin-BO1 | GIGSAILSAGKSIIKGLAKGLAEHF | Oriental Fire-bellied Toad | Anti-proliferative effects | MTT assay | Hep G2 | Human hepatoma | IC50 : 3.61 μM |
| dbacp01868 | Bombinin-BO1 | GIGSAILSAGKSIIKGLAKGLAEHF | Oriental Fire-bellied Toad | Anti-proliferative effects | MTT assay | SK-HEP-1 | Human hepatoma | IC50 : 8.08 μM |
| dbacp01869 | Bombinin-BO1 | GIGSAILSAGKSIIKGLAKGLAEHF | Oriental Fire-bellied Toad | Anti-proliferative effects | MTT assay | Huh8 | Human hepatoma | IC50 : 8.42 μM |
| dbacp01870 | Bombinin-BO1 | GIGSAILSAGKSIIKGLAKGLAEHF | Skin secretion, Oriental fire-bellied toad, China, Asia | Anti-proliferative effects | MTT assay | Hep G2 | Human hepatoma cancer | IC50 : 0.76 μM |
| dbacp01871 | Bombinin-BO1 | GIGSAILSAGKSIIKGLAKGLAEHF | Skin secretion, Oriental fire-bellied toad, China, Asia | Anti-proliferative effects | MTT assay | SK-HEP-1 | Human hepatoma cancer | IC50 : 3.75 μM |
| dbacp01872 | Bombinin-BO1 | GIGSAILSAGKSIIKGLAKGLAEHF | Skin secretion, Oriental fire-bellied toad, China, Asia | Anti-proliferative effects | MTT assay | Huh7 | Human hepatoma cancer | IC50 : 3.91 μM |
| dbacp03406 | Interferon gamma (IFN-gamma) | MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQIISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQLLPESSLRKRKRSRC | Mouse | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HL60 | Leukemia | IC50 ± SD : 9.3 ± 2.9μM |
| dbacp03407 | Interferon gamma (IFN-gamma) | MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQIISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQLLPESSLRKRKRSRC | Mouse | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | Daudi lymphoma cells | Lymphoma | IC50 ± SD : 5.2 ± 2.2μM |
| dbacp03408 | Interferon gamma (IFN-gamma) | MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQIISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQLLPESSLRKRKRSRC | Mouse | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HEK293 | Renal cancer | IC50 ± SD : > 250μM |
| dbacp05397 | Peptide deformylase, mitochondrial | MARLWGALSLWPLWAAVPWGGAAAVGVRACSSTAAPDGVEGPALRRSYWRHLRRLVLGPPEPPFSHVCQVGDPVLRGVAAPVERAQLGGPELQRLTQRLVQVMRRRRCVGLSAPQLGVPRQVLALELPEALCRECPPRQRALRQMEPFPLRVFVNPSLRVLDSRLVTFPEGCESVAGFLACVPRFQAVQISGLDPNGEQVVWQASGWAARIIQHEMDHLQGCLFIDKMDSRTFTNVYWMKVND | Human | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HL60 | Leukemia | IC50 ± SD : 9.3 ± 2.9 μM |
| dbacp05398 | Peptide deformylase, mitochondrial | MARLWGALSLWPLWAAVPWGGAAAVGVRACSSTAAPDGVEGPALRRSYWRHLRRLVLGPPEPPFSHVCQVGDPVLRGVAAPVERAQLGGPELQRLTQRLVQVMRRRRCVGLSAPQLGVPRQVLALELPEALCRECPPRQRALRQMEPFPLRVFVNPSLRVLDSRLVTFPEGCESVAGFLACVPRFQAVQISGLDPNGEQVVWQASGWAARIIQHEMDHLQGCLFIDKMDSRTFTNVYWMKVND | Human | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | Daudi lymphoma cells | Lymphoma | IC50 ± SD : 5.2 ± 2.2 μM |
| dbacp05399 | Peptide deformylase, mitochondrial | MARLWGALSLWPLWAAVPWGGAAAVGVRACSSTAAPDGVEGPALRRSYWRHLRRLVLGPPEPPFSHVCQVGDPVLRGVAAPVERAQLGGPELQRLTQRLVQVMRRRRCVGLSAPQLGVPRQVLALELPEALCRECPPRQRALRQMEPFPLRVFVNPSLRVLDSRLVTFPEGCESVAGFLACVPRFQAVQISGLDPNGEQVVWQASGWAARIIQHEMDHLQGCLFIDKMDSRTFTNVYWMKVND | Human | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HEK293 | Renal cancer | IC50 ± SD : >250 μM |
| dbacp05651 | Protein farnesyltransferase subunit beta | MASSSSFTYYCPPSSSPVWSEPLYSLRPEHARERLQDDSVETVTSIEQAKVEEKIQEVFSSYKFNHLVPRLVLQREKHFHYLKRGLRQLTDAYECLDASRPWLCYWILHSLELLDEPIPQIVATDVCQFLELCQSPDGGFGGGPGQYPHLAPTYAAVNALCIIGTEEAYNVINREKLLQYLYSLKQPDGSFLMHVGGEVDVRSAYCAASVASLTNIITPDLFEGTAEWIARCQNWEGGIGGVPGMEAHGGYTFCGLAALVILKKERSLNLKSLLQWVTSRQMRFEGGFQGRCNKLVDGCYSFWQAGLLPLLHRALHAQGDPALSMSHWMFHQQALQEYILMCCQCPAGGLLDKPGKSRDFYHTCYCLSGLSIAQHFGSGAMLHDVVMGVPENVLQPTHPVYNIGPDKVIQATTHFLQKPVPGFEECEDAVTSDPATD | Rat | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HL60 | Leukemia | IC50 : 9.3 ± 2.9 μM |
| dbacp05652 | Protein farnesyltransferase subunit beta | MASSSSFTYYCPPSSSPVWSEPLYSLRPEHARERLQDDSVETVTSIEQAKVEEKIQEVFSSYKFNHLVPRLVLQREKHFHYLKRGLRQLTDAYECLDASRPWLCYWILHSLELLDEPIPQIVATDVCQFLELCQSPDGGFGGGPGQYPHLAPTYAAVNALCIIGTEEAYNVINREKLLQYLYSLKQPDGSFLMHVGGEVDVRSAYCAASVASLTNIITPDLFEGTAEWIARCQNWEGGIGGVPGMEAHGGYTFCGLAALVILKKERSLNLKSLLQWVTSRQMRFEGGFQGRCNKLVDGCYSFWQAGLLPLLHRALHAQGDPALSMSHWMFHQQALQEYILMCCQCPAGGLLDKPGKSRDFYHTCYCLSGLSIAQHFGSGAMLHDVVMGVPENVLQPTHPVYNIGPDKVIQATTHFLQKPVPGFEECEDAVTSDPATD | Rat | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | Daudi lymphoma cells | Lymphoma | IC50 : 5.2 ± 2.2 μM |
| dbacp05653 | Protein farnesyltransferase subunit beta | MASSSSFTYYCPPSSSPVWSEPLYSLRPEHARERLQDDSVETVTSIEQAKVEEKIQEVFSSYKFNHLVPRLVLQREKHFHYLKRGLRQLTDAYECLDASRPWLCYWILHSLELLDEPIPQIVATDVCQFLELCQSPDGGFGGGPGQYPHLAPTYAAVNALCIIGTEEAYNVINREKLLQYLYSLKQPDGSFLMHVGGEVDVRSAYCAASVASLTNIITPDLFEGTAEWIARCQNWEGGIGGVPGMEAHGGYTFCGLAALVILKKERSLNLKSLLQWVTSRQMRFEGGFQGRCNKLVDGCYSFWQAGLLPLLHRALHAQGDPALSMSHWMFHQQALQEYILMCCQCPAGGLLDKPGKSRDFYHTCYCLSGLSIAQHFGSGAMLHDVVMGVPENVLQPTHPVYNIGPDKVIQATTHFLQKPVPGFEECEDAVTSDPATD | Rat | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HEK293 | Renal cancer | IC50 : > 250μM |